8 completed. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
| Phase 2 | 2 | Completed 2 |
Follow Hyperoxaluria: new trials by email Literature Review of Hyperoxaluria trials Research Report on Hyperoxaluria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 Lumasiran - Primary Hyperoxaluria Type 1, Primary Hyperoxaluria | Phase 3 | Completed | Alnylam Pharmaceuticals | 21 | 2020-01-21 | 2025-07-18 |
| A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 Lumasiran - Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1) | Phase 3 | Completed | Alnylam Pharmaceuticals | 18 | 2019-04-22 | 2025-02-14 |
| A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 Placebo, Lumasiran - Primary Hyperoxaluria Type 1 (PH1) | Phase 3 | Completed | Alnylam Pharmaceuticals | 39 | 2018-11-27 | 2024-08-12 |
| Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria ALLN-177, Placebo - Enteric Hyperoxaluria | Phase 3 | Completed | Allena Pharmaceuticals | 115 | 2018-05-21 | 2020-02-27 |
| A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria Oxabact OC5 - Oxalobacter formigenes HC-1, Placebo - Primary Hyperoxaluria | Phase 3 | Completed | OxThera | 25 | 2018-01-09 | 2021-12-10 |
| Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis Lanthanum Carbonate - Secondary Hyperoxaluria, Nephrolithiasis | Phase 3 | Completed | Universitair Ziekenhuis Brussel | 54 | 2017-08-18 | 2026-08-10 |
| Phase 2/3 Oxabact Study Oxalobacter formigenes, Placebo - Primary Hyperoxaluria | Phase 2 / Phase 3 | Completed | OxThera | 36 | 2009-12-01 | 2013-05-15 |
| Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients Oxalobacter formigenes, Placebo - Primary Hyperoxaluria | Phase 2 / Phase 3 | Completed | OxThera | 43 | 2007-10-01 | 2013-05-15 |
Hyperoxaluria, Primary (6) · Primary hyperoxaluria type 1 (3) · Kidney Calculi (1) · Nephrolithiasis (1) · Urolithiasis (1)
Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Kidney Diseases (8) · Male Urogenital Diseases (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Carbohydrate Metabolism, Inborn Errors (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Metabolic Diseases (6) · Metabolism, Inborn Errors (6) · Nutritional and Metabolic Diseases (6) · Calculi (1) · Nephrolithiasis (1)
lumasiran (3) · lanthanum carbonate (1) · oxalate decarboxylase (1) · reloxaliase (1)
Alnylam Pharmaceuticals (3) · OxThera (3) · Allena Pharmaceuticals (1) · Universitair Ziekenhuis Brussel (1)
United States (7) · France (5) · Germany (5) · United Kingdom (4) · Belgium (3) · Israel (3) · Netherlands (3) · Italy (2) · Spain (2) · United Arab Emirates (2) · Australia (1) · Canada (1) · Jordan (1) · Lebanon (1) · Switzerland (1)
Annamaria Kausz, MD MS (1) · Christian Tielemans, MD, PhD (1) · Dawn Milliner, M.D (1) · Dawn Milliner, M.D. (1) · Gesa Schalk, MD (1)
PMID 38332115, PMID 33789010, PMID 34906487, PMID 35843439, PMID 35913563, PMID 38319254, PMID 39355649, PMID 41343248
2018 (2), 2019 (1), 2023 (1)